Markus Landthaler

This inventor holds 8 USPTO granted patents. Top assignees: The Rockefeller University, Max-Delbruck-Centrum Fur Molekulare Medizin in Der Helmholtz-Gemeinschaft. Active years: 2010-2020.

USPTO Granted Patents = 8

% Patents Active = 12.5

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

New York, NY (US) (2010 - 2015)
Berlin, DE (2014 - 2020)

Company Filing History:

7 out of 751

The Rockefeller University

patents

1 out of 23

Max-Delbruck-Centrum Fur Molekulare Medizin in Der Helmholtz-Gemeinschaft

patents

Years Active: 2010-2020

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10731163 - Oligonucleotide targeted to the A20-3' untranslated region (2020-08-04),

2. 8937173 - Anti-microRNA oligonucleotide molecules (2015-01-20),

3. 8841073 - Methods for identifying RNA segments bound by RNA-binding proteins or ribonucleoprotein complexes (2014-09-23),

4. 8816060 - Anti-microRNA oligonucleotide molecules (2014-08-26),

5. 8318926 - Anti-MicroRNA oligonucleotide molecules (2012-11-27),

6. 8114985 - Anti-MicroRNA oligonucleotide molecules (2012-02-14),

7. 7943756 - Anti-microRNA oligonucleotide molecules (2011-05-17),

8. 7772389 - Anti-microRNA oligonucleotide molecules (2010-08-10),

Title: The Innovations of Markus Landthaler

Introduction

Markus Landthaler is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of molecular medicine, particularly in the development of oligonucleotide therapies. With a total of 8 patents to his name, Landthaler's work has the potential to impact the treatment of various diseases, including cancer and autoimmune disorders.

Latest Patents

Among his latest patents is an antisense oligonucleotide targeted to the A20-3' untranslated region. This invention comprises a sequence aimed at the 3' untranslated region (3' UTR) of the TNFAIP3 (A20) transcript, which can be utilized as a medicament for treating cancer or autoimmune diseases. Another notable patent involves anti-microRNA oligonucleotide molecules, which relates to isolated anti-microRNA molecules and provides methods for inhibiting microRNP activity in a cell.

Career Highlights

Throughout his career, Markus Landthaler has worked with esteemed institutions such as The Rockefeller University and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association. His research has focused on advancing our understanding of molecular mechanisms and developing innovative therapeutic strategies.

Collaborations

Landthaler has collaborated with notable scientists, including Thomas Tuschl and Gunter Meister. These partnerships have fostered a collaborative environment that has led to groundbreaking discoveries in the field of molecular biology.

Conclusion

Markus Landthaler's contributions to the field of molecular medicine through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for new therapeutic approaches in treating complex diseases.